Navigation Links
Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
Date:4/18/2012

BANNOCKBURN, Ill., April 18, 2012 /PRNewswire/ --Pinnacle Biologics is pleased to announce the appointment of Bioprojet Pharma, effective March 15, 2012, as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN (Porfimer Sodium) in select European countries.  

Ethyol is a cytoprotective agent indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) following radiation treatment for head and neck cancer and to reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with ovarian cancer.  Bioprojet has rights to distribute Ethyol in France, Italy, Spain, Germany, the Benelux and other countries in the Pinnacle territory where the product is approved by the regulatory authorities.

Photofrin is a photo-activated drug and is indicated for the treatment of thoracic malignancies, specifically non-small cell lung cancer and esophageal cancer.  Bioprojet has rights to distribute the product initially in France, Germany and the United Kingdom.

About Pinnacle Biologics

Pinnacle Biologics Inc., a privately held bio-pharmaceutical company, specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. The company is based in the U.S.A with its headquarters in Bannockburn, Illinois; and its European subsidiary, Pinnacle Biologics BV,is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.

About Bioprojet Pharma

Bioprojet Pharma is a privately held European pharmaceutical company with is headquarters in Paris, France.  Bioprojet is a leading European research based specialty pharmaceutical company involved in the design and development of compounds from pre-clinical to Phase III.  The company markets pharmaceutical products across Europe.

Contact Information:
Pinnacle Biologics Inc.
'/>"/>

SOURCE Pinnacle Biologics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pinnacle Oncology LLC Acquires Rights to Unique Radioprotector From the University of Chicago
2. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
3. Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
4. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
5. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
8. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
9. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Research and Markets ... Cancer Market 2014-2018" report to their offering. ... growth of cancerous cells in the breast tissue. It ... cancer is rare. Histologically, breast cancer can be classified ... undifferentiated carcinoma. Ductal carcinoma is the form of breast ...
(Date:9/16/2014)... , 17. September 2014 ... ), hat heute die Markteinführung des ... Probenverarbeitung, in Europa bekannt gegeben. Der ... Universalplattform zur Vereinfachung der präanalytischen Probenverarbeitung. ... und fehlerbehaftete Arbeitsschritte bei der manuellen ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
Breaking Medicine Technology:Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
... N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed a new drug application under Section ... (FFDCA) with the U.S. Food and Drug Administration (FDA) ... and 40 mg tablets.  Watson,s rosuvastatin zinc tablets are ...
... Oct. 27 Intrinsic Bioprobes today announced that ... issued US Patent 7,816,095 covering novel blood protein ... first of a series of patent applications that ... clinical utility. "The biomarkers were discovered ...
Cached Medicine Technology:Watson Confirms Crestor® Patent Challenge 2Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... 17, 2014 Lintelus, Inc., a ... it has released Lintelus Meeting Version 3.1, designed ... corporate events. The newest release includes features to ... management capabilities and allow a more personalized event ... Lintelus Meeting 3.1 offers product advancements including real-time ...
(Date:9/17/2014)... HERNDON, VIRGINIA (PRWEB) September 17, 2014 ... top rhinoplasty specialist surgeons, has been recognized as a recipient ... is reserved for only the best of the best as ... by specialty. , Dr. Naderi, who is affectionately known by ... of only a handful of true rhinoplasty specialist ...
(Date:9/17/2014)... Promising new research published in the ... on the potential ability of ketones to support brain ... The study shows that brain hypometabolism associated ... impaired glucose uptake and/or utilization, and results suggest that ... The study, by the Research Center on Aging and ...
(Date:9/17/2014)... TENN. September 16, 2014) A study led ... found the chemotherapy dose threshold below which male ... sperm production. The study appears in September 17 ... , By clarifying which patients are at highest ... expect the findings to eventually increase use of ...
Breaking Medicine News(10 mins):Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 3Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3
... , , WEDNESDAY, Nov. 14 (HealthDay News) -- During a ... drugs to be sold by pharmacists without a prescription, ... for and against the proposal by representatives of various ... day,s end, the FDA officials said they weren,t ready ...
... a,statement from Jeff Levi, Executive Director of Trust ... (TFAH) urges Congress to override the,President,s veto of ... Agencies Appropriations bill., The Labor/HHS bill provides ... states, territories, localities and hospitals to prepare for,public ...
... Kalamazoo, Mich.-based,Stryker Corporation and its former outpatient ... pay the United States $16.6,million to settle ... and other federal health care programs, the ... allegations that Physiotherapy, which is based,in Memphis, ...
... announced today,that the U.S. Food and Drug ... beta) for the treatment of anemia,associated with ... patients,on dialysis and patients not on dialysis. ... (CKD). MIRCERA is the only FDA-approved,erythropoiesis-stimulating agent ...
... Conference Call Scheduled for November 20, NAPA, Calif., ... specialty life sciences company engaged in the,study of senescense, ... skincare,and dermatological therapeutics today announced financial results for the,quarter ... quarter 2007 were $469,000 compared to,$2,027,000 for the same ...
... Natural Nutrition,(OTC Bulletin Board: NNTN) ( http://www.naturalnutritioninc.com ) ... of 10-QSB. Chris Mathers, CFO of,Natural Nutrition said, ... filing for Natural Nutrition will not be filed ... record revenue of $12.644,million and record EBITDA of ...
Cached Medicine News:Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Stryker Corp. & Physiotherapy Associates to Pay U.S. $16.6 Million for Alleged False Claims to Federal Health Care Programs 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:Natural Nutrition to Report Record Revenue and EBITDA in Late Filing of 10-QSB 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Aspen® CTO combines highly effective immobilization of ... a level of comfort that makes it ... substantially progressive immobilization in going from a ... and then on to a four-post orthosis. ...
... Shoulder Immobilizer with Contoured ... Navy cotton sling with foam-padded ... body straps. Quick-release closure buckles. ... 35 covered abduction wedge to ...
The Humeral Stabilizing System is a terrific option for immobilization of stable humeral fractures, stablesupracondular fractures, and biceps/triceps repairs....
Medicine Products: